Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

EPL Oil & Gas Q1 net income increases

EPL Oil & Gas, Inc., an oil and natural gas exploration and production company, has reported a net income of $29.04 million, or $0.73 per diluted share, for the first quarter ended March 31, 2013, compared to $1.50 million, or $0.04 per diluted share, for the first quarter ended March 31, 2012.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

Andhra Bank Q4 net profit up

Andhra Bank, has reported a net profit of INR3.44 billion, or INR6.16 per share, for the fourth quarter ended March 31, 2013, compared to INR3.4 billion, or INR6.07 per share, for the same quarter ended March 31, 2012.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

M/A-COM reports net income for Q2, provides outlook for Q3

M/A-COM Technology Solutions Holdings, Inc. has reported that net income attributable to common stockholders for the second quarter ended March 29, 2013 was $8.09 million, or $0.17 per diluted share, compared to a net loss attributable to common stockholders of $54.76 million, or $8.02 loss per diluted share, for the same quarter ended March 30, 2012. The company expects revenue to be in the range of $78 million to $82 million for the third quarter of fiscal 2013.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

Madalena Ventures Q4 net loss increases

Madalena Ventures Inc., an upstream oil and gas company, has reported a net loss of C$5.07 million, or C$0.02 loss per share, for the fourth quarter ended December 31, 2012, compared to a net loss of C$1.58 million, or C$0.01 loss per share, for the fourth quarter ended December 31, 2011.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

Zogenix announces positive results from extended Phase I schizophrenia trial

Zogenix, Inc., a pharmaceutical company developing products for the treatment of central nervous system disorders and pain, has announced positive results from its extended Phase I clinical trial of Relday, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

West Pharmaceutical reports higher Q1 net income, provides outlook for 2013

West Pharmaceutical Services, Inc., a provider of systems for packaging and delivery of injectable drugs, has reported that net income for the first quarter ended March 31, 2013 was $31.7 million, or $0.90 per diluted share, compared to $29.2 million, or $0.81 per diluted share, for the same quarter ended March 31, 2012. The company expects diluted EPS to be in the range of $3.08 to $3.23 for 2013.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

Sedasys receives premarket approval for CAPS system

Sedasys, a division of Ethicon Endo-Surgery, Inc., has received premarket approval, or PMA, from FDA for the SEDASYS System, a computer-assisted personalized sedation, or CAPS, system.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

SoftBank annual net income down

SoftBank Corp., a provider of telecommunications and internet services, has reported that net income for fiscal 2013 was JPY289.4 billion, compared to JPY313.7 billion for fiscal 2012.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

Primus Canada and Costco renew agreement for telecommunications services

Primus Telecommunications Canada Inc. has announced a multi-year renewal of a partnership program as exclusive national provider of residential telecommunications services to Costco members.

Published By MarketLine
16 May 2013
NewsWire
NewsWire

Sigma-Tau Pharmaceuticals launches CYSTARAN

Sigma-Tau Pharmaceuticals, Inc., a subsidiary of the Sigma-Tau Group, has launched CYSTARAN 0.44%, an FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Published By MarketLine
16 May 2013

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.